Tradename | Company | Number | Date | Products |
---|---|---|---|---|
VOXZOGO | BioMarin Pharmaceutical | N-214938 RX | 2021-11-19 | 3 products, RLD, RS |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
achondroplasia | — | D000130 | Q77.4 |
dwarfism | HP_0003510 | D004392 | E34.31 |
Expiration | Code | ||
---|---|---|---|
VOSORITIDE, VOXZOGO, BIOMARIN PHARM | |||
2030-10-20 | ODE-449 | ||
2028-11-19 | ODE-387 | ||
2026-11-19 | NCE | ||
2026-10-20 | NPP |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Achondroplasia | D000130 | — | Q77.4 | 2 | 5 | 2 | — | — | 9 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Turner syndrome | D014424 | Orphanet_881 | Q96 | — | 1 | — | — | — | 1 |
Drug common name | Vosoritide |
INN | vosoritide |
Description | Vosoritide, sold under the brand name Voxzogo, is a medication used for the treatment of achondroplasia.
|
Classification | Protein |
Drug class | peptides: atrial natriuretic type substances |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | 1480724-61-5 |
RxCUI | — |
ChEMBL ID | CHEMBL3707276 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB11928 |
UNII ID | 7SE5582Q2P (ChemIDplus, GSRS) |